Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Albendazole-Ivermectin on Lymphatic Filariasis in Mali
NCT02784743Phase 4Completed
- Sponsor
- Centre d'Appui à la lutte contre la Maladie
- Start
- May 2001
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of albendazole and ivermectin in lymphatic filariasis (LF), sponsored by Centre d'Appui à la lutte contre la Maladie. Primary endpoint: Vector infection and infectivity rates at 7 months. Started May 2001; status: completed.
02
Drugs
albendazoleivermectin
03
Conditions
lymphatic filariasis (LF)
Beyond the preview
Go deeper on NCT02784743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784743.